TETRAULT LYNN A. 4

Accession 0001104659-24-098944

CIK 0001649904other

View on SEC.gov Company Profile

Filed

Sep 10, 8:00 PM ET

Accepted

Sep 11, 4:31 PM ET

Size

22.3 KB

Accession

0001104659-24-098944

Insider Transaction Report

Form 4

Period: 2024-09-09

RHYTHM PHARMACEUTICALS, INC.RYTM

TETRAULT LYNN A.

Director

Transactions

Exercise/Conversion
Stock Option (right to buy)
2024-09-09−3,199→ 7,501 total
Exercise: $18.99Exp: 2031-06-08→ Common Stock (3,199 underlying)
Sale
Common Stock
2024-09-10$49.05/sh−8,490$416,418→ 12,011 total
Exercise/Conversion
Stock Option (right to buy)
2024-09-10−10,000→ 0 total
Exercise: $4.15Exp: 2032-06-07→ Common Stock (10,000 underlying)
Exercise/Conversion
Stock Option (right to buy)
2024-09-10−7,501→ 0 total
Exercise: $18.99Exp: 2031-06-08→ Common Stock (7,501 underlying)
Exercise/Conversion
Common Stock
2024-09-10$18.99/sh+7,501$142,444→ 20,501 total
Exercise/Conversion
Common Stock
2024-09-09$18.99/sh+3,199$60,749→ 6,199 total
Exercise/Conversion
Common Stock
2024-09-10$4.15/sh+10,000$41,500→ 13,000 total
Sale
Common Stock
2024-09-10$50.60/sh−350$17,710→ 3,000 total
Sale
Common Stock
2024-09-09$50.04/sh−3,199$160,068→ 3,000 total
Sale
Common Stock
2024-09-10$50.20/sh−8,661$434,796→ 3,350 total

Footnotes (6)

[F1]The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted on May 13, 2024.
[F2]The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $50.00 to $50.25. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
[F3]The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $48.53 to $49.52. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
[F4]The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $49.54 to $50.50. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
[F5]The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $50.55 to $50.71. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
[F6]The option is fully vested and exercisable.

Documents

1 file

4
tm2423816-2_4seq1.xmlPrimary
OWNERSHIP DOCUMENT

Issuer

RHYTHM PHARMACEUTICALS, INC.

CIK 0001649904

→

Entity typeother

Related Parties

filerCIK 0001645512

Filing Metadata

Form type: 4
Filed: Sep 10, 8:00 PM ET
Accepted: Sep 11, 4:31 PM ET
Size: 22.3 KB

View on SEC.gov